BCL2L2 is a probable target for novel 14q11.2 amplification detected in a non-small cell lung cancer cell line

Cancer Science

Volumn 98, Issue 7, 2007, Pages 1070-1077

  Kawasaki, Tsutomu ^a,b   Yokoi, Sana ^a,c   Tsuda, Hitoshi ^c,d   Izumi, Hiroyuki ^a   Kozaki, Ken Ichi ^a,c   Aida, Shinsuke ^d   Ozeki, Yuichi ^d   Yoshizawa, Yasuyuki ^b   Imoto, Issei ^a,c   Inazawa, Johji ^a,c  

^a Tokyo Medical and Dental University ^*  (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN BCL 2; PROTEIN BCL 2 LIKE 2 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; AMPLICON; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CELL IMMORTALIZATION; CHROMOSOME 14Q; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE ACTIVATION; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RNA INTERFERENCE; TUMOR DIFFERENTIATION;

BCL-X PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; CELL LINE, TUMOR; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 14; DOWN-REGULATION; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 34249904163     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00491.x     Document Type: Article

References (38)

1. Watanabe Y, Ozasa K, Nagura J et al. Mortality in the JACC study till 1999. J Epidemiol 2005; 15 (Suppl. 1): S74-9.
2. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005; 23: 2556-68.
3. Snijders AM, Nowak N, Segraves R et al. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet 2001; 29: 263-4.
4. Albertson DG, Pinkel D. Genomic microarrays in human genetic disease and cancer. Hum Mol Genet 2003; 12: 145-52.
5. Inazawa J, Inoue J, Imoto I. Comparative genomic hybridization (CGH)-arrays pave the way for identification of novel cancer-related genes. Cancer Sci 2004; 95: 559-63.
6. Schwab M. Oncogene amplification in solid tumors. Semin Cancer Biol 1999; 9: 319-25.
7. Imoto I, Yang ZQ, Pimkhaokham A et al. Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell. Cancer Res 2001; 61: 6629-34.
8. Yokoi S, Yasui K, Saito-Ohara F et al. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol 2002; 161: 207-16.
9. Takada H, Imoto I, Tsuda H et al. Screening of DNA copy-number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization. Cancer Sci 2005; 96: 100-10.
10. Tanami H, Tsuda H, Okabe S et al. Involvement of cyclin D3 in liver metastasis of colorectal cancer, revealed by genome-wide copy-number analysis. Laboratory Invest 2005; 85: 1118-29.
11. Yu W, Imoto I, Inoue J, Onda M, Emi M, Inazawa J. A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity. Oncogene 2007; 26: 1178-87.
12. Izumi H, Inoue J, Yokoi S et al. Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. Hum Mol Genet 2005; 14: 997-1007.
13. Imoto I, Izumi H, Yokoi S et al. Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers. Cancer Res 2006; 66: 4617-26.
14. Masuda A, Kondo M, Saito T et al. Establishment of human peripheral lung epithelial cell lines (HPL1) retaining differentiated characteristics and responsiveness to epidermal growth factor, hepatocyte growth factor, and transforming growth factor β1. Cancer Res 1997; 57: 4898-904.
15. Reddel RR, Ke Y, Gerwin BI et al. Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. Cancer Res 1998; 48: 1904-9.
16. UICC. TNM. Classification of Malignant Tumours, 6th edn. Geneva: UICC, 2002.
17. Watanabe Y. TNM classification for lung cancer. Ann Thorac Cardiovasc Surg 2003; 9: 343-50.
18. Tsuchiya R. The Japanese database for the staging of lung cancer. Ann Ital Chir 1999; 70: 905.
19. Kitinya JN, Sueishi K, Tanaka K, Katsuda Y. Immunoreactivity of surfactant-apoprotein in adenocarcinomas, large cell and small cell carcinomas of the lung. Acta Pathol Jpn 1986; 36: 1271-8.
20. Kaufmann T, Schinzel A, Borner C. Bcl-w (edding) with mitochondria. Trends Cell Biol 2004; 14: 8-12.
21. Gibson L, Holmgreen SP, Huang DC et al. Bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene 1996; 13: 665-75.
22. O'Reilly LA, Print C, Hausmann G et al. Tissue expression and subcellular localization of the pro-survival molecule Bcl-w. Cell Death Differ 2001; 8: 486-94.
23. Wilson JW, Nostro MC, Balzi M et al. Bcl-w expression in colorectal adenocarcinoma. Br J Cancer 2000; 82: 178-85.
24. Kitamura S, Kondo S, Shinomura Y. Met/HGF receptor modulates bcl-w expression and inhibits apoptosis in human colorectal cancers. Br J Cancer 2000; 83: 668-73.
25. Lee HW, Lee SS, Lee SJ, Um HD. Bcl-w is expressed in a majority of infiltrative gastric adenocarcinomas and suppresses the cancer cell death by blocking stress-activated protein kinase/c-Jun NH2-terminal kinase activation. Cancer Res 2003; 63: 1093-100.
26. Gibson L, Holmgreen SP, Huang DC et al. Bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene 1996; 13: 665-75.
27. Antonsson B. Bax and other pro-apoptotic Bcl-2 family killer proteins and their victim, the mitochondrion. Cell Tissue Res 2001; 306: 347-61.
28. Print CG, Loveland KL, Gibson L et al. Apoptosis regulator bcl-w is essential for spermatogenesis but appears otherwise redundant. Proc Natl Acad Sci USA 1998; 95: 12.424-31.
29. Weinstein IB. Cancer: Addiction to oncogenes - The Achilles heal of cancer. Science 2002; 297: 63-4.
30. Weinstein IB, Joe AK. Mechanisms of disease: Oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006; 3: 448-57.
31. Hubner A, Jaeschke A, Davis RJ. Oncogene addiction: Role of signal attenuation. Dev Cell 2006; 11: 752-4.
32. Kim YH, Girard L, Giacomini CP et al. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene 2006; 25: 130-8.
33. Bae IH, Park MJ, Yoon SH et al. Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase-2 expression via phosphoinositide 3-kinase, Akt, and Sp1. Cancer Res 2006; 66: 4991-5.
34. Garraway LA, Sellers WR. Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer 2006; 6: 593-602.
35. Deng S, Zhou H, Xiong R et al. Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics. Breast Cancer Res Treat Sep 27 2006 [Epub ahead of print].
36. Voorhees PM, Dees EC, O'Neil B et al. The proteasome as a target for cancer therapy. Clin Cancer Res 2003; 9: 6316-25.
37. Zender L, Spector MS, Xue W et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006; 125: 1253-67.
38. Yang ZQ, Streicher KL, Ray ME, Abrams J, Ethier SP. Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer. Cancer Res 2006; 66: 11.632-43.